US Pharma MarketingThe post Day One concludes patient enrolment for tovorafenib’s FIREFLY-2 trial appeared first on Clinical Trials Arena.
Day One concludes patient enrolment for tovorafenib’s FIREFLY-2 trial
Day One Biopharmaceuticals has concluded patient enrolment in the Phase III FIREFLY-2 trial assessing tovorafenib for pLGG. Preliminary insights from the Phase III trial are anticipated to be available in 2027. The trial will explore the oral tovorafenib monotherapy for patients with RAF-altered pLGG who require initial systemic therapy. Credit: TheCorgi / Shutterstock.com. Day One Biopharmaceuticals has concluded patient enrolment in the Phase III FIREFLY-2 trial assessing tovorafenib for paediatric low-grade glioma (pLGG). The randomised, global, open-label, multi-centre trial is evaluating the safety, efficacy, and tolerability of tovorafenib, compared to standard of care chemotherapy, as a first-line therapy for patients…
Day One Biopharmaceuticals has concluded patient enrolment in the Phase III FIREFLY-2 trial assessing tovorafenib for pLGG.
Source: Clinical Trials Arena